Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Miragen Therapeutics (MGEN) Competitors

Miragen Therapeutics logo

MGEN vs. OPGN, ENZ, SLS, TVRD, PRQR, SGHT, NGNE, OABI, CRDF, and MDWD

Should you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include OpGen (OPGN), Enzo Biochem (ENZ), SELLAS Life Sciences Group (SLS), Tvardi Therapeutics (TVRD), ProQR Therapeutics (PRQR), Sight Sciences (SGHT), Neurogene (NGNE), OmniAb (OABI), Cardiff Oncology (CRDF), and MediWound (MDWD). These companies are all part of the "medical" sector.

Miragen Therapeutics vs. Its Competitors

Miragen Therapeutics (NASDAQ:MGEN) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

In the previous week, Miragen Therapeutics' average media sentiment score of 0.00 equaled OpGen'saverage media sentiment score.

Company Overall Sentiment
Miragen Therapeutics Neutral
OpGen Neutral

2.7% of OpGen shares are held by institutional investors. 1.1% of Miragen Therapeutics shares are held by company insiders. Comparatively, 43.8% of OpGen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Miragen Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, OpGen has a beta of -1.66, meaning that its share price is 266% less volatile than the S&P 500.

OpGen has a net margin of -1,140.36% compared to Miragen Therapeutics' net margin of -1,393.50%. OpGen's return on equity of 0.00% beat Miragen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Miragen Therapeutics-1,393.50% -141.66% -88.74%
OpGen -1,140.36%N/A -287.58%

OpGen has lower revenue, but higher earnings than Miragen Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Miragen Therapeutics$4.46M13.92-$41.87M-$20.09-0.79
OpGen$2.67M18.57-$32.67MN/AN/A

Summary

OpGen beats Miragen Therapeutics on 6 of the 9 factors compared between the two stocks.

Get Miragen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MGEN vs. The Competition

MetricMiragen TherapeuticsMedical Laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$62.10M$22.63M$5.47B$8.92B
Dividend YieldN/A119.72%5.24%4.04%
P/E Ratio-1.49N/A27.0520.14
Price / Sales13.927.00380.7693.83
Price / CashN/AN/A26.2128.59
Price / Book2.340.218.005.58
Net Income-$41.87M-$27.15M$3.16B$248.40M

Miragen Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MGEN
Miragen Therapeutics
N/A$15.89
+1.4%
N/A+27.2%$62.10M$4.46M-1.4945High Trading Volume
OPGN
OpGen
N/A$4.76
-0.4%
N/A+88.0%$47.92M$2.67M0.00100Gap Down
ENZ
Enzo Biochem
N/A$0.33
-14.8%
N/A-69.3%$17.03M$29.09M0.00520Gap Down
High Trading Volume
SLS
SELLAS Life Sciences Group
0.1236 of 5 stars
$2.08
-5.0%
N/A+79.3%$218.51M$1M0.0010News Coverage
TVRD
Tvardi Therapeutics
N/A$22.15
-5.1%
$71.50
+222.8%
N/A$218.39M$7.14M0.0080
PRQR
ProQR Therapeutics
2.1135 of 5 stars
$2.01
-1.5%
$8.00
+298.0%
+25.9%$214.63M$20.46M-5.74180News Coverage
SGHT
Sight Sciences
1.386 of 5 stars
$4.07
-1.5%
$4.10
+0.7%
-44.0%$213.50M$79.87M0.00210News Coverage
NGNE
Neurogene
3.7905 of 5 stars
$19.19
+28.4%
$46.17
+140.6%
-42.9%$213.22M$930K0.0090Positive News
High Trading Volume
OABI
OmniAb
2.5994 of 5 stars
$1.74
flat
$7.00
+302.3%
-51.0%$212.51M$26.39M0.007
CRDF
Cardiff Oncology
1.6974 of 5 stars
$3.51
+11.4%
$9.88
+181.3%
+65.2%$209.56M$680K-3.8220Analyst Forecast
High Trading Volume
MDWD
MediWound
1.6372 of 5 stars
$19.20
-0.9%
$31.80
+65.6%
-1.7%$209.35M$20.22M-9.1980News Coverage

Related Companies and Tools


This page (NASDAQ:MGEN) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners